What we're reading, December 28, 2015: patients fight for Medicaid coverage of expensive hepatitis C treatment, Express Scripts develops programs to protect insurer's from pricey new drugs, and Republicans divided over Medicaid expansion.
Individuals are pushing back at states that are restricting access to curative treatment for hepatitis C, citing cost reasons. Patients in Indiana—one of 34 states where Medicaid refuses to pay for the $95,000 Harvoni unless there’s proof of liver damage—have filed a class action lawsuit to gain access to the pill and ensure Medicaid covers for it, according to a report by the National Public Radio.
By developing optional programs that include newer expensive drugs, Express Scripts is protecting its clients and their budgets from going topsy-turvy, reports AIS Health. With the Hepatitis Cure Value and Cholesterol Care Value Programs in place, the benefit manager is planning to unveil the Oncology Care Value Program and the Inflation Protection Program come January 2016. With an initial focus on prostate cancer, lung cancer, and renal cell carcinoma, patients covered by participating plans will receive “clinically appropriate and cost-effective medication for a specific indication,” according to Express Scripts senior vice president, Clinical, Research & New Solutions, and Chief Innovation Officer Glen Stettin, MD.
Republicans are divided over the Affordable Care Act (ACA), especially when it comes to Medicaid expansion in the states. According to The New York Times, Republican state governors who want to expand the reach of the ACA within their state are facing grief from Republican members in Congress who do not believe the law holds credibility. While Republican governors in Arizona, Arkansas, Indiana, Iowa, Michigan, Nevada, New Jersey, New Mexico, and Ohio, have expanded Medicaid, governors of South Dakota, Tennessee, and Utah are working towards it.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More